ABSTRACT Transfection of transgenes into Drosophila cultured cells is a standard approach for studying gene function. However, the number of transgenes present in the cell following transient transfection or stable random integration varies, and the resulting differences in expression level affect interpretation. Here we developed a system for Drosophila cell lines that allows selection of cells with a single-copy transgene inserted at a specific genomic site using recombination-mediated cassette exchange (RMCE). We used the fC31 integrase and its target sites attP and attB for RMCE. Cell lines with an attP-flanked genomic cassette were transfected with donor plasmids containing a transgene of interest (UAS-x), a dihydrofolate reductase (UAS-DHFR) gene flanked by attB sequences, and a thymidine kinase (UAS-TK) gene in the plasmid backbone outside the attB sequences. In cells undergoing RMCE, UAS-x and UAS-DHFR were exchanged for the attP-flanked genomic cassette, and UAS-TK was excluded. These cells were selected using methotrexate, which requires DHFR expression, and ganciclovir, which causes death in cells expressing TK. Pure populations of cells with one copy of a stably integrated transgene were efficiently selected by cloning or mass culture in $6 weeks. Our results show that RMCE avoids the problems associated with current methods, where transgene number is not controlled, and facilitates the rapid generation of Drosophila cell lines in which expression from a single transgene can be studied. KEYWORDS RMCE; Drosophila; cell line; single-transgene expression M AMMALIAN cultured cells can be genetically modified by site-specific insertion of transgenes using homologous recombination and various recombinase systems (Branda and Dymecki 2004; Sorrell and Kolb 2005) . In contrast, transgenes are introduced into Drosophila cultured cells either by transient transfection or by stable transformation following random integration of transgenes together with a selectable marker (Eschalier 1997; Cherbas and Cherbas 2007) . These methods fail to provide control of transgene expression because the number of transgene copies in the cells varies greatly. Moreover, in stably transformed lines, the sites of insertion vary, and each will be subject to position effects on gene expression (Spradling and Rubin 1983) . For these reasons, methods that involve site-specific introduction of single transgenes into Drosophila tissue culture cells would be a significant improvement.
M AMMALIAN cultured cells can be genetically modified by site-specific insertion of transgenes using homologous recombination and various recombinase systems (Branda and Dymecki 2004; Sorrell and Kolb 2005) . In contrast, transgenes are introduced into Drosophila cultured cells either by transient transfection or by stable transformation following random integration of transgenes together with a selectable marker (Eschalier 1997; Cherbas and Cherbas 2007) . These methods fail to provide control of transgene expression because the number of transgene copies in the cells varies greatly. Moreover, in stably transformed lines, the sites of insertion vary, and each will be subject to position effects on gene expression (Spradling and Rubin 1983) . For these reasons, methods that involve site-specific introduction of single transgenes into Drosophila tissue culture cells would be a significant improvement.
Homologous recombination has been attempted in Drosophila cell culture, but the levels of nonspecific recombination observed make the approach unsatisfactory (Cherbas and Cherbas 1997) . Several site-specific recombination systems have been used successfully in whole flies, including uC31, which mediates recombination between two heterotypic target sites referred to as attP and attB (Groth et al. 2004; Venken et al. 2006; Bischof et al. 2007) . Insertion results in two new sites (attL and attR) that are not targets of the integrase, thus producing an irreversible change. uC31-mediated integration also can occur in Drosophila S2 cells, a commonly used Drosophila cell line, as shown by the successful recombination between two transfected plasmids each carrying either a single attB or attP site (Groth et al. 2004) . uC31-mediated insertion of DNA sequences also can be achieved by recombinase-mediated cassette exchange (RMCE) (Baer and Bode 2001; Bateman et al. 2006) . In this case, an attP-flanked genomic cassette is replaced by an attB-flanked donor sequence. This approach has been used in mammalian cultured cells and in many whole organisms, including Drosophila (Branda and Dymecki 2004; Venken and Bellen 2005; Bateman et al. 2006) . RMCE was demonstrated in S2 cells by the exchange of an mCherry sequence for an enhanced green fluorescent protein (EGFP) sequence, and cells that had undergone RMCE were sorted by the expression of EGFP (Neumuller et al. 2012) . However, providing a selection for cells with RMCE-mediated integration would simplify the method and increase stringency. In tissue culture cells, RMCE events, in which a cassette with a resistance gene is inserted, can be distinguished from insertions of the whole plasmid by including a gene that causes toxicity in the plasmid backbone. Resistance selects for all transformants, and toxicity provides counterselection against transformants with random insertions, insertions in single attP sites, and insertions into pseudotarget sites that may be present in the genome. Here we have developed a RMCE-based protocol and selection scheme for inserting single-copy transgenes at a specific site in Drosophila tissue culture cells. The method is efficient and allows the generation of pure lines with single targeted insertions in $6 weeks.
Materials and Methods

Fly stocks
The following fly stocks were used UAS-Ras V12 (Karim and Rubin 1998) , P[attP.w + .attP]JB89B (Bateman et al. 2006) (Bloomington Stock #25091), and Act5C-Gal4/TM6 (Bloomington Stock #3954). A recombinant third chromosome, UAS-Ras V12 , P[attP.w + .attP]JB89B, was generated.
Primary cultures and cell lines
Embryos were collected overnight from a cross of Act5C-Gal4/ TM6 3 UAS-Ras V12 , P[attP.w + .attP]JB89B/TM3 flies. Primary cultures were generated from the embryos using an established method (Simcox 2013) . Cultures were established at 22°and passaged when they reached confluence at $3 weeks. Two independent lines, Ras-attP-L1 and RasattP-L2, were established and maintained at either 22 or 25°. Each is a continuous cell line that has been passaged for over 400 cell doublings. Schneider's Insect Medium (Sigma) with 10% FBS was used for cell culture.
Karyotyping
Cells at about 50% confluence were incubated with a final concentration of 0.01 mg/ml of N-desacetyl-N-methylocolchicine (KaryoMAX, Gibco) for 2 h. Cells were harvested with trypsin, washed in PBS, and resuspended in 5 ml of 0.075 M KCl (hypotonic solution) for 20 min. Four drops of fix (3:1 methanol: glacial acetic acid) were added, and the cells were centrifuged, resuspended in 3 ml of fix, and incubated for 10 min. Cells were centrifuged, resuspended in a small quantity of fix, and spotted onto clean slides. Slides were mounted in VECTASHIELD with DAPI (Vector Laboratories), and approximately 50 mitotic spreads were scored for each cell line.
Cloning
Two vector plasmids were generated for this study. pDoubleDonor is a derivative of pBlueScript (Supporting Information, Figure S1 ). pDoubleDonor was modified to produce pMCS-Donor, which has a multiple-cloning site (MCS) for insertion of other transgenes (details of cloning are provided in File S1).
pMCS-Donor was used as a vector for insertion of three different transgenes, a-Tubulin84B, Jupiter, and Cas9. a-Tubulin and Jupiter cDNAs, with an HA tag and a UAS-hsp70 promoter, were amplified using PCR from UFO03193 (a-Tub84B-RA) and UFO09974 (Jupiter-RD) from the Drosophila Genomics Resource Center's tagged ORF collection. The fragments were cloned into the AvrII/NdeI sites in the pMCS-Donor plasmid. For the Cas9 gene, the CMV promoter in the pCas-9_GFP plasmid (Addgene #44719) was replaced with a UAS-hsp70 promoter. This was accomplished by adding a UAS-hsp70 promoter sequence to the first 288 bp of the Cas9 sequence using overlapping PCR and the primers FP. UAS.hsp70.SpeI, FP.UAS.Cas9.overlap, RP.Cas9.EcoRV, and RP.UAS.Cas9.overlap. This PCR product then was used to replace the CMV promoter and the first 288 bp of pCas-9_GFP. The resulting plasmid was digested with SpeI and BsrGI, and the Cas9-containing fragment was cloned into SpeI and Acc65I sites in pMCS-Donor.
A plasmid, pU6-GuideRNA.CG4096, encoding a guide RNA for targeting Cas9 to CG4096 was generated. To construct this plasmid, a U6 promoter sequence was amplified from Drosophila melanogaster genomic DNA using the primers FP. U6prom.EcoRI and RP.U6prom.HindIII. Overlapping PCR was used to add a chimeric CRISPR guide RNA with BbsI sites to the U6 promoter sequence using primers FH.CRISPR.U6intro, SH.CRISPR.U6intro, and RP.CRISPR.U6.BamHI. The resulting PCR product with the U6 promoter and chimeric CRISPR guide RNA was cloned into the EcoRI/BamHI site in pBluescript (pBS KS 2 ) to generate the pU6-GuideRNA plasmid. pU6-GuideRNA was digested with BbsI, and a CG4096-targeting sequence was added by annealed oligo cloning of CG4096CRISPRsense and CG4096CRISPRanti oligos to generate pU6-GuideRNA.CG4096. The sequence for a scrambled version of the CG4096-targeting sequence (SC) was similarly added to pU6-GuideRNA using annealed oligo cloning of ScCRISPRsense and ScCRISPRanti oligos to generate pU6-GuideRNA.SC.
PCR analysis of genomic DNA
Genomic DNA was isolated from cells using a DNeasy genomic DNA isolation kit (Qiagen), and PCR was conducted with Taq (NEB). The following primer pairs were used to analyze genomic DNA:
Wild-type tara locus: FP.tara.5pUTR and RP.tara.Intron; attP.w + .attP in tara locus: FP.P-elem-5p and RP.tara.Intron; RMCE orientation 1: P-elem-3 and 5P-DHFR-rev (distal to tara); 5P-SV40-fwd and Tara-rev (proximal to tara); RMCE orientation 2: P-elem-3 and 5P-SV40-fwd (distal to tara); 5P-DHFR-rev and Tara-rev (proximal to tara); TK: TK-fwd and TK-rev; and Oda: Oda.fwd and Oda.rev.
Analysis of mutations following CRISPR/Cas9 targeting
Cells expressing Cas9 (integrated by RMCE) were transfected with pU6-GuideRNA.CG4096, a plasmid encoding a guide RNA targeting sequence against CG4096 or a control scrambled sequence pU6-GuideRNA.SC. Genomic DNA was isolated from the cells 36 h after transfection, and the region flanking the CRISPR/Cas9 target sequence was amplified using Phusion (NEB)-mediated PCR and primers FP.CG4096. PCR and RP.CG4096.PCR. Mutations were detected using the PCR product and the Surveyor Mutation Detection Kit (Transgenomic) following the manufacturer's recommended protocol that cuts at mismatched sequences resulting from CRISPR/Cas9-induced deletions and insertions.
Transfection and selection
Ras-attP-L1 or Ras-attP-L2 cells were plated at 70-80% confluence in a 25-cm 2 flask. The cells were transfected the following day with 0.5-1 mg of donor plasmid and 1-2 mg of uC31 integrase plasmid (pUAS-dphiC31) using Effectene Transfection Reagent (Qiagen) according to the manufacturer's protocol. After 24 h, the cells were harvested and diluted 1:4 into one or more 25-cm 2 flasks with medium containing 2 3 10 27 M methotrexate (MTX). MTX selects for transfected cells with the dihydrofolate reductase (UAS-DHFR) gene from the donor plasmid. Then, $6 days later, ganciclovir (GCV) was added to a final concentration of 10 mM. GCV selects against cells with a UAS-TK gene. Throughout the selection, cells were split as they reached confluence and maintained in medium with MTX and GCV. A selection period of four to seven passages was required to produce a uniform population of cells expressing GFP. This was accomplished in $6 weeks because each passage was a 1:4 dilution of the cells, and the time between passages at 25°was $5 days. Figure S2 summarizes the protocol.
Cell cloning
Cells were transfected in a 25-cm 2 T-flask. The next day, cells were harvested and plated at 2 3 10 5 cells per well in a sixwell plate in medium with MTX (2 3 10 27 M). GCV was added together with MTX or 3 or 6 days after MTX. In $3 weeks, all wells had colonies of cells, but starting GCV selection 6 days after MTX produced, on average, about twice the number of colonies. Colonies were isolated by scraping and simultaneously aspirating the cells with a 100-ml pipette tip. Colonies were expanded by initially seeding the cells into 24-well plates. Figure S2 summarizes the protocol.
Western blot analysis
Cells were lysed in modified TN1 lysis buffer (125 mM NaCl, 20 mM Tris, pH 8.0, 10 mM EDTA, 10 mM Na 4 P 2 O 7 Á0.10H 2 O, 10 mM EGTA, 1% v/v Triton X-100, and 1 mM Na 3 VO 4 ) supplemented with 13 Protease Inhibitor Cocktail (Roche) and centrifuged at 80003g, and the supernatant was mixed with loading dye (2% w/v SDS, 8% v/v glycerol, 10 mM Tris, pH 6.8, 400 mM DTT, and 0.01% w/v bromophenol blue). Total protein was separated in a 10% w/v polyacrylamide gel and transferred to a PVDF membrane for antibody analysis. Rabbit anti-GFP (Sigma, G1544) was used at a 1:10,000 dilution, and mouse anti-tubulin (Sigma, T9026) was used at a 1:5000 dilution. Following enhanced chemiluminescent staining of the blots (Advansta WesternBright ECL, K-12045-D50), densitometric analyses were performed on the scanned images of X-ray films using ImageJ. GFP levels from individual colonies were normalized to a-tubulin levels and then compared.
Immunohistochemistry
Cells were stained for HA-tagged proteins as described earlier (Simcox 2013 ) using a mouse anti-HA (Sigma, H3663) antibody at a 1:1000 dilution.
Primers
Primers used in this study follow and are shown in the 59-to-39 orientation. Lowercase letters indicate regions of annealing for overlapping PCR. 
Results
Generation of continuous cell lines with an attP-flanked genomic cassette
Expression of activated Ras V12 is an efficient means to generate continuous cell lines in D. melanogaster (Simcox et al. 2008a, b) . Here we used this method to establish lines that also harbored a genomic cassette encoding the mini-white (w + ) gene flanked by inverted attP sequences on the third chromosome at the taranis (tara) locus (P[attP.w + .attP]JB89B) (Bateman et al. 2006) . We generated a third-chromosome recombinant strain with attP.w + .attP and a UAS-Ras V12 transgene inserted in Multidrug resistance protein 4 ortholog/ CG14709 (Simcox et al. 2008b) . These flies were crossed to Act5C-Gal4 flies, and embryos from the cross were used to generate primary cultures ( Figure 1A ). Cells expressing Ras V12 (Act5C-Gal4/attP.w + .attP, UAS-Ras V12 ) rapidly became the dominant cell type in the culture because they have reduced apoptosis and a growth advantage (Simcox et al. 2008a) .
We established two cell lines (Ras-attP-L1 and Ras-attP-L2) from these primary cultures. The cell lines have a polyclonal origin, but both appear to have limited cell diversity consisting of one or two cell types based on cell morphology and karyotype. Ras-attP-L1 cells have a uniform spindle-shaped morphology and adhere firmly to the surface ( Figure 1B) . RasattP-L2 cells have two distinct morphologies, an adherent type and a round type that is loosely attached ( Figure 1C ). Cells from both lines are diploid for the second and third chromosomes, with variations in the number of fourth and sex chromosomes (Figure 2 ). The chromosome analysis was conducted when the cells had been passaged .100 times, suggesting that the karyotypes are stable. Based on sex chromosome makeup, cells in the Ras-attP-L1 line are either female, XX (Figure 2B ), or male, XO ( Figure 2C) , and in keeping with this, analysis of RNA extracted from the cells shows both the female and male patterns of splicing for the transformer (tra) gene ( Figure S3 ). Ras-attP-L2 cells are male, XO ( Figure  2D) , and show the male pattern for tra ( Figure S3 ).
To be able to insert one transgene by RMCE, it is important that the cells are heterozygous so that one third chromosome has the attP.w + .attP cassette in the tara locus and the other has the wild-type tara locus (Figure 1) . Consistent with this, DNA analysis showed that both lines are heterozygous for the tara alleles ( Figure 2F ). In cases where we examined colonies derived from single cells, these also were heterozygous for third-chromosome alleles ( Figure S4 ). These data suggest that most cells in the population are heterozygous, but we cannot rule out the possibility that there are cells within the population that have undergone genetic changes to generate cells that are homozygous for the alleles.
Donor vectors
We constructed two donor vectors, one that gave a visual readout of RMCE events using UAS-GFP and UAS-RFP as marker genes (pDoubleDonor) and one with a MCS (pMCS-Donor), which is a vector for cloning transgenes of interest ( Figure S1 ). Both vectors also contain UAS-dihydrofolate reductase (UAS-DHFR), which confers resistance to MTX and UAS-thymidine kinase (UAS-TK), which confers sensitivity to GCV. When present, UAS-GFP and UAS-DHFR are within the inverted attB sites, and UAS-TK and UAS-RFP are outside the attB sites. All genes have UAS binding sites and are regulated by Gal4, which is constitutively expressed by the cells (Act5C-Gal4) (Figure 1) . We also used a plasmid encoding uC31 integrase (pUAS-dphiC31) ( Figure S1 ), which was cotransfected to cause recombination between the genomic attP and donor-plasmid attB sites.
Demonstration of RMCE in cells
Ras-attP-L1 and Ras-attP-L2 cells were transfected with pDoubleDonor DNA and plasmid DNA encoding the uC31 integrase ( Figure S1 and Figure S2 ). Approximately 20% of In all samples, the donor sequence is present in both orientation 1 and orientation 2. The TK gene is only present in cells from early passages (E) and is lost following continued selection in GCV in late passages (L). The Ornithine decarboxylase antizyme (Oda) gene serves as a control.
cells were transfected based on expression of RFP and/or GFP ( Figure S2 ). Initially, most of the transfected cells expressed both GFP and RFP, and only rare cells expressed GFP alone. RMCE is expected to result in GFP-only-expressing cells because the cassette exchange would exclude the RFP gene ( Figure 3A) . Selection in MTX alone allows cells with a copy(s) of the UAS-DHFR gene from random insertion or RMCE to survive (Figure 3, A and B) . Small colonies of marked cells were apparent in $10 days. These grew into large clones and, as expected for MTX-only selection, were positive for RFP and GFP or positive for GFP only (Figure 3, C-F) . The GFP-onlyexpressing cells showed lower GFP fluorescence ( Figure 3D ). This is consistent with the presence of only one copy of the UAS-GFP gene, which is expected following RMCE.
To select for RMCE events, GCV was added to the medium after 6 days in MTX ( Figure S2 ). Cells in which the transgene had inserted at a single attP site or randomly would retain the UAS-TK gene (and UAS-RFP) and be sensitive to GCV ( Figure  3B ). In keeping with this, we found that addition of GCV selected against RFP-expressing cells so that, after approximately four to seven passages (each passage is a 1:4 dilution at 25°), only cells expressing GFP were present in the cultures ( Figure S2 ). The genotype of these cells confirmed that RMCE resulted in insertion of UAS-DHFR and UAS-GFP transgenes at the attP site because the expected junction sequences could be amplified using PCR of genomic DNA (Figure 4) . In early passages, cells harboring a UAS-TK gene were still present, but with continued counterselection, the TK gene could no longer be detected, and cells with only RMCE events were selected (Figure 4) . The cells have a polyclonal origin and, as expected, harbored transgenes that inserted in either of two orientations possible with RMCE between sequences flanked by inverted attP and attB sites (Figure 4 ).
RMCE-inserted transgenes are stably retained in the absence of drug selection
RMCE-mediated insertion of a transgene is expected to be a stable event. To test this, Ras-attP-L1 cells with inserted UAS-DHFR/UAS-GFP transgenes were split, and one culture was grown without drugs for 10 passages. A PCR test for a fragment that spans the integration site showed that the UAS-DHFR/UAS-GFP transgenes remained stably integrated after 10 passages without drug selection, and the cells were still GFP positive ( Figure S5 ).
Frequency of RMCE events
To determine the frequency of RMCE events, we plated transfected Ras-attP-L1 cells at low density and counted colonies following selection in MTX. We used Ras-attP-L1 for cell cloning experiments because the cells are strongly adherent ( Figure 1B) , and colonies remain coherent. On day 10 after transfection, we scored the number of colonies and whether the cells were positive for GFP, GFP and RFP, or RPF. More than 100 colonies were counted for each of three independent transfections. RFP-only colonies were rare (5%) and may derive from cells in which the GFP gene is mutant or lost. Approximately 59% of colonies were GFP and RFP, which is expected after random or single-site insertion of the donor plasmid ( Figure 3B ). Approximately 36% colonies were GFP only, which is expected after RMCE ( Figure 3A) . The number of GFPonly colonies varied among experiments (28, 36, and 43%), and, on average, 0.18% of transfected cells underwent RMCE. Figure 5 GFP expression is similar from transgenes inserted in either orientation following RMCE. (A) PCR analysis of parental RasattP-L1(2) and independent cell clones (pDD-C1 and pDD-C2) that have undergone RMCE (with pDoubleDonor) and selection in MTX and GCV. Cell clone pDD-C1 has the transgene cassette inserted in orientation 1, and cell clone pDD-C2 has the transgene cassette inserted in orientation 2. (B) Western blotting analysis shows that the clones express similar levels of GFP. pDD-C1: pDD-C2 = 1: 1.06 6 0.07 (n = 3; GFP levels were first normalized to a-Tubulin). The parental line lacks the transgene and does not express GFP. a-Tubulin is a loading control. (C) Phase and GFP images of the cells show that the clones express similar levels of GFP (pDD-C1 and pDD-C2). The parental line lacks the transgene and does not express GFP.
More colonies derived from random (or single-site) insertion than RMCE insertion, which means that counterselection is required. The cells not undergoing RMCE are killed by GCV because they still harbor the TK gene. To determine the optimal time for the counterselection, we varied the time at which GCV was added (together with MTX or 3 or 6 days after starting MTX). During selection in both drugs (MTX and GCV), the sensitive cells, which slowly stopped growing, provided a "feeder layer" for the resistant cells. Colonies of resistant cells were seen with all regimes, but starting GCV selection 6 days after MTX produced, on average, about twice the number of colonies. A lag before adding GCV may allow time for RMCE events to resolve and eliminate the TK gene.
Clones with transgenes inserted in either orientation express similar levels of protein During RMCE, the transgene can insert in either orientation because the attP sites are indirect repeats (Figure 4) . To determine whether there was a bias in orientation or a difference in transgene expression depending on orientation, we examined colonies of cells derived from single RMCE events. We analyzed 11 independent colonies and found that inserts in 8 were orientation 1, 1 was orientation 2, and 2 had both orientations. Colonies with cells having both orientations were likely to be derived from two independent clones growing close together on the plate. Orientation 1 was more frequent, but the reason for this is unknown. It is unlikely to be a consequence of differential transgene expression because we found similar levels of GFP expression in cells with transgenes in either orientation ( Figure 5 ). Both orientations were found in cells that were selected in mass culture (Figure 4) . However, we determined orientation in these cell populations by nonquantitative PCR analysis, and the fraction of cells with a given orientation was not determined. In practice, it appears to be unnecessary to clone the cells because transgene expression was similar in either orientation.
Expressing transgenes using the pMCS-Donor vector
We developed the pMCS-Donor vector for cloning and expression of transgenes of interest ( Figure S1 ). UAS transgenes encoding HA-tagged cDNAs for a-Tubulin84B and Jupiter were cloned into the pMCS-Donor plasmid and transfected into Ras-attP-L1 cells. Cells were selected for RMCE-mediated insertion of the transgenes and stained for expression of the HA-tagged proteins. a-Tubulin and Jupiter were robustly expressed in the cells and associated with the cytoskeleton, as expected for their known function ( Figure 6A) .
To test the function of a transgene, we selected for cells with an RMCE-inserted copy of a Streptococcus pyogenes Cas9 transgene with a C-terminal GFP tag. Western blotting analysis showed that the protein was expressed ( Figure 6B) . To test the function of Cas9, the cells were transfected with a CRISPR plasmid (U6-SgRNA) encoding a guide RNA targeting the gene CG4096. PCR analysis of genomic DNA from the cells showed that some had the expected deletions in CG4096, confirming that Cas9 was functional ( Figure 6B ).
Discussion
We have developed an efficient system using RMCE for inserting single transgenes into a specific site in Drosophila Figure 6 The pMCS-Donor can be used to express single-copy transgenes of choice. (A) Transgenes encoding HA-tagged a-Tubulin and Jupiter were cloned into the pMCS-Donor plasmid using the MCS. Cell lines with a single transgene were generated by RMCE. The cell lines expressed the tagged proteins with a cytoskeletal localization pattern that is consistent with their known function. (B) A cell line expressing a GFP-tagged Cas9 gene was generated using RMCE. The cells were transfected with a plasmid encoding a guide RNA targeting the CG4096 gene. SURVEYOR analysis (Transgenomic) showed cleavage of the target gene and recovery of fragments of the expected size (arrowheads). A scrambled guide sequence control (SC) had no effect.
tissue culture cells. The parental cell lines used in the protocol were derived from flies harboring an attP-flanked cassette that provides a site for exchange with donor sequences bounded by attB sites. To purify only cells that have undergone RMCE, we designed vectors that work with a two-drug combination. The first drug, MTX, selects for cells with a DHFR resistance gene, and the second, GCV, selects against TK. In the vectors, DHFR and the transgene of interest are within the attB sites, whereas the TK gene is in the plasmid backbone. All insertion mechanisms result in resistance to MTX, but only RMCE allows cells to survive in the presence of GCV because the TK gene is excluded. This positive-negative drug combination is essential for selecting a pure population of cells with insertion of a transgene at a single site because without counterselection, random insertions persist. The frequency of RMCE events is $0.18% of transfected cells, and a cell line in which cells have a transgene inserted by RMCE can be established in $6 weeks.
In the work described here, we generated cell lines with an attP-flanked cassette, but the method is not limited to these lines or the generation of new cell lines with a similar cassette. Rather, it could be used with any existing cell line that has undergone genome editing with CRISPR/Cas9 to insert an attP-flanked cassette in the desired locus. Subsequent modification of this site by RMCE would allow introduction of any sequence of interest. This two-step process is essential because insertion of donor sequences using homology-directed repair of a CRISPR/Cas9-induced lesion does not allow for counterselection against cells with unaltered alleles. Reports on homologous recombination in S2 cells using CRISPR/Cas9 suggest that even with drug selection, approximately half the alleles are not altered (Bassett et al. 2014; Bottcher et al. 2014) . Donor sequence size also may limit the application of homologous recombination, whereas this is not likely to be limiting in RMCE. We inserted a 7-kb fragment including the Cas9 gene, and in flies, RMCE has been used to insert 50-to 100-kb fragments (Bateman et al. 2013; Venken et al. 2006) .
Inserting Drosophila transgenes in vivo has reached a very sophisticated level and employs multiple recombination systems including P-transposase, Cre, Flp, Minos transposase, and uC31 integrase. These systems can be used sequentially to modify an initial inserted sequence to both remove segments and insert new sequences (e.g., Alexandre et al. 2014) . In flies, these systems are site specific because random integration of DNA is rare, whereas in cultured cells random integration following transfection occurs at high frequency. Here we have demonstrated that uC31-mediated RMCE and a double-selection system to eliminate cells with random insertions allow recovery of cells with single-copy transgenes. A similar strategy could be developed for other recombinases that would allow subsequent reengineering of the transgenic locus in the cells, as has been done in vivo.
In conclusion, we expect that the RMCE method will be useful for in vitro applications, including the analysis of structure-function relationships, protein complexes, gene regulatory regions, and signaling pathways. The insertion of single-copy transgenes at a specific genomic locus by RMCE allows for comparative analysis between transgenic lines that have similar levels of transgene expression. This offers a major advance and mitigates the inherent variation in site and number of transgenes following random integration or transient expression. This plasmid has GFP and DHFR sequences within the attB sites and RFP and TK sequences outside the attB sites. pDoubleDonor was used in this study to give a visual readout of RMCE. Cells undergoing RMCE will be GFP positive only. Cells with insertions of the whole plasmid will be GFP and RFP positive. (B) pMCS-Donor. This plasmid has a multiple cloning site (MCS) and can be used to insert a transgene of interest using the unique restriction sites indicated. (C) pUAS-dφC31. This plasmid encodes a dφC31 integrase, which is optimized for Drosophila codon usage. pUAS-dφC31 is transfected together with a donor plasmid into Ras-attP cells to mediate recombination between the genomic attP cassette and the attB sites in the donor plasmid. All genes have a UAS sequence for regulation by Gal4 (the RasattP cells have an Act5C-Gal4 gene). DHFR confers resistance to MTX and TK causes sensitivity to GCV. RT-PCR for the transformer (tra) gene was performed on RNA extracted from male and female flies and the cell lines, Ras-attP-L1 and Ras-attP-L2. In males and females, there is a non-specific constitutive product (arrow). In females there is an additional product derived from an alternatively spliced RNA only expressed in females (arrowhead). Both cell lines express the constitutive tra product (arrow), whereas, Ras-attP-L1 cells also express the female specific product (arrowhead). The Ras-attP-L1 cell line is a mixture of XX and XO cells consistent with the observed female and male pattern of tra gene expression. The Ras-attP-L2 cell line has XO cells consistent with the male pattern of tra gene expression. Figure S4 . RMCE-derived colonies are heterozygous for the tara locus. Cells were transfected with pDoubleDonor and selected in MTX and GCV. PCR analysis showed that colonies with an RMCE event have a copy of the wild type tara locus (above) and an allele with an insertion of the transgene ( Figure 5 ).
GENETICS
Figure S5
Continued drug selection is not required to maintain cells with an RMCE-inserted transgene. Cells were transfected with pDoubleDonor and selected initially with both MTX and GCV. Three independent transfections were performed (T1-3). Once a pure RMCE population was obtained, cells were split and one culture was grown without drugs for ten passages. (A) A PCR test for a fragment that spans the integration site shows the RMCE event was stable with and without drug. (B) Cells continued to express GFP in the absence of drug, and no RFP positive cells were observed. Most cells (98%) show GFP expression, with variations in level, possibly correlating with the cell cycle.
File S1
Methods: pDoubleDonor was generated by modification of a pBlueScript (pBS-KS+) vector. A BglII site was introduced between NotI and XbaI sites of pBS-KS+ by annealed oligo cloning which also mutated the XbaI site, and generated pBS-KS-XbaI*-BglII. Two attB sites were added to pBS-KSXbaI*-BglII plasmid at the SacI/SacII and ClaI/XhoI restriction sites by annealed oligo cloning creating pBS-attB. In parallel, DHFR, TK, GFP and RFP genes were amplified by PCR and cloned into pBS-KS+ plasmids as XbaI fragments. These genes were then subcloned into the XbaI site in a pUAST vector in frame with the UAS-hsp70 promoter. The pUAST vector with DHFR gene was digested with BamHI and a fragment with the UAS-hsp70-DHFR-SV40 cassette was cloned into the BglII site in the pBS-attB vector creating the pBS-attB-DHFR plasmid. This cloning mutated the BglII site in pBS-attB vector and a new BglII site was introduced between XhoI and KpnI sites in the vector by annealed oligo cloning. A BamHI fragment from pUAST vector with the UAS-hsp70-EGFP-SV40 cassette from the corresponding pUAST clone was then cloned into the BamHI site within the attB sites of pBS-attB-DHFR to create pBS-attB-DHFR-GFP plasmid. The UAS-hsp70-RFP-SV40 cassette and UAS-TK-SV40 cassette were individually cloned into the BglII site in pBS-KS-XbaI*-BglII creating pBS-TK and pBS-RFP plasmids. pBS-TK was digested and cloned downstream of the RFP gene in pBS-RFP with SpeI and KpnI creating pBS-RFP-TK. pBS-RFP-TK was digested with SacII, and treated with Klenow fragment to create a blunt end, and then digested with KpnI to isolate the RFP-TK cassette. This was cloned into XhoI/KpnI sites in a pBSattB-DHFR-GFP vector, that had been XhoI digested plasmid treated with Klenow fragment to create a blunt end. This created a pBS-attB-DHFR-GFP-attB-RFP-TK plasmid, which we call pDoubleDonor.
To construct pMCS-Donor, the UAS-TK and UAS-RFP genes in pDoubleDonor were replaced by a UAS-TK gene that was amplified by PCR from pDoubleDonor, and an MCS sequence was introduced between the EcoRI-ClaI sites by inserting a DNA fragment generated by annealing FP.MCS.Oligo and RP.MCS.Oligo.
FP.MCS.Oligo:AATTCCTTAAGCCTAGGGGATCTTTCGAAAGATCTGGTACCGCTAGCCATATG GTCGACCTCGAGAT
